Business Context and Reporting Period
Autonomix Medical, Inc. (AMIX), an emerging growth company incorporated in Delaware, filed this Form 8-K on November 18, 2025. The report details a private placement transaction closed on November 19, 2025, involving the sale of equity securities to an institutional investor.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $5.0 million from the offering, excluding warrant exercise proceeds and before deducting fees.
- Securities Issued:
- 4,501,666 Pre-Funded Warrants (exercisable at $0.001 per share).
- 9,003,332 Series C Common Warrants (exercisable at $0.8607 per share).
- Combined Purchase Price: $1.1097 per unit (one Pre-Funded Warrant plus accompanying Common Warrants).
- Placement Agent Fees: Up to 8% of gross proceeds plus up to $50,000 in expense reimbursement.
- Use of Proceeds: Working capital and general corporate purposes.
The filing does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels as this is a current report on a specific transaction rather than a periodic financial statement.
Material Changes and Restrictions
The primary material change is the dilution of existing shareholders due to the issuance of approximately 13.5 million shares of common stock (upon full exercise of warrants) and the receipt of $5.0 million in gross capital. The company has agreed to a 60-day lock-up period from the effective date of the registration statement regarding the sale of equity securities. Additionally, the company is restricted from entering into Variable Rate Transactions for six months post-registration, with an exception for "at-the-market" offerings if the share price exceeds $1.1107.
Outlook, Risks, and Contingencies
- Registration Timeline: The company must file a registration statement within 20 days of the agreement and use commercially reasonable efforts to have it declared effective within 60 days (or 90 days if reviewed by the SEC).
- Warrant Terms: Common Warrants expire 5.5 years from issuance and may be exercised on a cashless basis after six months if no registration statement is available. Fundamental transaction provisions allow holders to receive the Black Scholes Value of their warrants in cash or consideration.
- Ownership Caps: Exercise is limited to prevent the holder from exceeding 4.99% (or up to 9.99% at election) of outstanding shares for Common Warrants, and 9.99% for Pre-Funded Warrants.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8% placement fee and $50,000 expense reimbursement.
- Confirm the effective date of the registration statement to determine the start of the 60-day lock-up period.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific representations and warranties.
- Monitor the company's ability to maintain a share price above $1.1107 to utilize the at-the-market offering exception.
- Assess the impact of the 13.5 million potential new shares on existing shareholder dilution.